Profound Medical Corp. (NASDAQ:PROF) Holdings Lifted by Raymond James Trust N.A.

Raymond James Trust N.A. grew its holdings in shares of Profound Medical Corp. (NASDAQ:PROF) by 14.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,000 shares of the company’s stock after buying an additional 1,500 shares during the period. Raymond James Trust N.A.’s holdings in Profound Medical were worth $96,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Royce & Associates LP lifted its holdings in Profound Medical by 0.6% in the third quarter. Royce & Associates LP now owns 569,298 shares of the company’s stock worth $4,529,000 after purchasing an additional 3,500 shares during the period. Thompson Davis & CO. Inc. raised its position in shares of Profound Medical by 9.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 74,800 shares of the company’s stock worth $628,000 after buying an additional 6,150 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Profound Medical in the 3rd quarter worth approximately $612,000. 47.86% of the stock is currently owned by institutional investors and hedge funds.

Profound Medical Price Performance

NASDAQ:PROF opened at $8.15 on Friday. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11. The business’s 50-day moving average price is $7.76 and its 200 day moving average price is $8.46. Profound Medical Corp. has a 52-week low of $7.11 and a 52-week high of $11.42. The firm has a market cap of $201.00 million, a P/E ratio of -6.08 and a beta of 0.83.

Analyst Upgrades and Downgrades

Separately, Raymond James upgraded shares of Profound Medical to a “strong-buy” rating in a research note on Saturday, November 9th.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.